NDASUBCUTANEOUSSOLUTION
Approved
Oct 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
6/8 — Strong
FUROSCIX (furosemide injection 80 mg/ 10 ml) by Scpharmaceuticals is 12. Approved for edema in pediatric patients weighing 43 kg, above, chronic kidney disease and 1 more indications. First approved in 2022.
Drug data last refreshed 2h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
FUROSCIX is a subcutaneous furosemide injection (80 mg/10 mL) approved in October 2022 as a loop diuretic for managing edema in patients with heart failure and chronic kidney disease. It works by inhibiting sodium and chloride reabsorption in the renal tubules, producing diuresis comparable to intravenous administration with a duration of up to 8 hours. The subcutaneous route offers a novel delivery alternative to traditional IV bolus dosing.
$0.009BPart D
Peak13.2 years to LOEEarly-stage commercial product at peak adoption phase with modest Medicare utilization; team expansion likely tied to market penetration efforts in heart failure and CKD segments.
Mechanism of Action
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…
Worked on FUROSCIX at Scpharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.